Caitong International Asset Management’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6 Sell
5
-22,290
-100% -$35.4K ﹤0.01% 2704
2026
Q1
$36.1K Buy
22,295
+22,025
+8,157% +$45.2K 0.01% 875
2025
Q4
$759 Buy
+270
New +$627 ﹤0.01% 1407
2025
Q2
Sell
-2,282
Closed -$7.17K 2085
2025
Q1
$7.17K Buy
2,282
+936
+70% +$3.7K 0.01% 935
2024
Q4
$5.84K Buy
+1,346
New +$4.21K 0.01% 1024

Other funds holding CRDF

Caitong International Asset Management's CRDF Position: Q2 2026 in Review

Caitong International Asset Management reduced its Cardiff Oncology (CRDF) stake by 100% in Q2 2026, selling an estimated $35.4K and leaving 5 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #2704.

Caitong International Asset Management first reported a position in CRDF in Q4 2024 and has held it in 5 quarters since. The position peaked at $36.1K in Q1 2026. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Caitong International Asset Management held 5 shares of Cardiff Oncology worth $6 as of Q2 2026.
  • Caitong International Asset Management sold 22,290 Cardiff Oncology shares in Q2 2026, an estimated $35.4K.
  • Cardiff Oncology made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2704 holding.
  • Caitong International Asset Management first reported a position in Cardiff Oncology in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Cardiff Oncology position peaked at $36.1K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.